Molecular Pathology Test For Risk Of Serious Liver Disease Within 5 Years (enhanced Liver Fibrosis (elf) Test) in New Jersey
Estimated using RAND 2024 commercial-to-Medicare ratios. Actual prices vary by insurer, plan, and facility.
Top Providers in New Jersey
| Provider | Medicare | Services |
|---|---|---|
| Quest Diagnostics Incorporated | $172.02 | 192 |
| Laboratory Corporation Of America... | $171.93 | 182 |
New Jersey Pricing in Context
In New Jersey, CPT code 0014M (Molecular Pathology Test For Risk Of Serious Liver Disease Within 5 Years (enhanced Liver Fibrosis (elf) Test)) carries an average Medicare payment of $171.98 — 0% below the national benchmark of $172.16. 2 providers across the state submitted claims for this procedure in 2023, performing 374 total services. Individual payments in NJ ranged from N/A at the low end to N/A at the high end, reflecting differences in provider setting (office vs. facility), modifiers, and the specific geographic locality code applied within the state.
The average billed charge in New Jersey is $460.11, which is the figure uninsured patients would most likely encounter before any negotiation or charity discount. Medicare, by statute, only reimburses the allowed amount — the balance between billed and paid is written off under provider participation agreements. Insured patients generally pay a negotiated rate that falls between these two figures; the exact amount depends on plan design, deductible status, and in-network participation. Because New Jersey sits below the national Medicare average, commercial rates in the state may also run lower than the US median.
Using RAND 2024 commercial-to-Medicare ratios for Other procedures, the estimated commercial insurance price in New Jersey lands near $438.54, with self-pay cash prices typically around $255.51. Before scheduling, patients can request a Good Faith Estimate under the No Surprises Act, compare cash rates from hospital Machine-Readable Files, and confirm whether the provider is in-network with their specific plan. This page presents CMS reference data for informational use; it does not constitute medical or financial advice.
Frequently Asked Questions
How much does Molecular Pathology Test For Risk Of Serious Liver Disease Within 5 Years (enhanced Liver Fibrosis (elf) Test) cost in New Jersey?
The average Medicare payment for Molecular Pathology Test For Risk Of Serious Liver Disease Within 5 Years (enhanced Liver Fibrosis (elf) Test) in New Jersey is $171.98, which is 0% below the national average of $172.16. Providers in NJ typically bill $460.11 for this procedure.
What does Molecular Pathology Test For Risk Of Serious Liver Disease Within 5 Years (enhanced Liver Fibrosis (elf) Test) cost with insurance in New Jersey?
With commercial insurance in New Jersey, Molecular Pathology Test For Risk Of Serious Liver Disease Within 5 Years (enhanced Liver Fibrosis (elf) Test) costs an estimated $438.54. Without insurance, the estimated cash price is $255.51. These estimates are based on RAND 2024 commercial-to-Medicare ratios and vary by insurer, plan, and facility.
How many providers perform Molecular Pathology Test For Risk Of Serious Liver Disease Within 5 Years (enhanced Liver Fibrosis (elf) Test) in New Jersey?
2 providers in New Jersey billed Medicare for Molecular Pathology Test For Risk Of Serious Liver Disease Within 5 Years (enhanced Liver Fibrosis (elf) Test) in 2023, performing 374 total services. Medicare payments ranged from N/A to N/A depending on the provider.
Is Molecular Pathology Test For Risk Of Serious Liver Disease Within 5 Years (enhanced Liver Fibrosis (elf) Test) cheaper in New Jersey than the national average?
Yes — Molecular Pathology Test For Risk Of Serious Liver Disease Within 5 Years (enhanced Liver Fibrosis (elf) Test) costs 0% below the national average in New Jersey. The state average Medicare payment is $171.98 compared to $172.16 nationally. Factors like local cost of living, provider competition, and regional Medicare fee schedules all influence state-level pricing.
Related Guides
Related Data Sources
Data from CMS Medicare Physician & Other Practitioners (2023).
Read our methodology — how this data is sourced, computed, and verified.